Tesamorelin is a synthetic analog of human GHRH(1-44) with a trans-3-hexenoyl group attached to the N-terminal tyrosine. The lipid modification confers resistance to dipeptidyl peptidase-IV cleavage, extending its functional half-life relative to native GHRH.
Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped ~4 days from our lab.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Identity
Parameter
Value
Sequence
trans-3-hexenoyl-Tyr¹-hGHRH(1-44)
Molecular formula
C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight
5135.86 g/mol
CAS number
901758-09-6
Length
44 residues
Quality
Test
Specification
HPLC purity
99.04%
Mass confirmation
ESI-MS within 0.5 Da
Net peptide content
≥ 80% by AAA
Endotoxin
< 0.5 EU/mg (LAL)
Bioburden
< 10 CFU/g
Residual TFA
< 1.0%
Lot LM-2715
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Canada. Retain samples held under storage spec for five years from release date.
Verification
Method
Result
ESI-MS (positive)
5135.9 Da (theor. 5135.86)
Amino acid analysis
82.1% net peptide
LAL endotoxin
< 0.05 EU/mg
Karl Fischer (water)
2.8% w/w
Reconstitution
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0-2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2-8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Selected references
Falutz J et al. Effects of tesamorelin on visceral fat in HIV lipodystrophy. N Engl J Med. 2007;357(23):2359-2370.
Stanley TL et al. Effects of tesamorelin on hepatic fat. Lancet HIV. 2019;6(12):e821-e830.
Ferdinandi ES et al. Pharmacokinetics of tesamorelin. Clin Pharmacokinet. 2007;46(4):331-343.
